We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Improved Survival of Elderly-fit Patients With Acute Myeloid Leukemia Requiring Intensive Therapy: 3-Year Multicenter Analysis From TALWG.
- Authors
Owattanapanich, Weerapat; Utchariyaprasit, Eakkapol; Tantiworawit, Adisak; Rattarittamrong, Ekarat; Niparuck, Pimjai; Puavilai, Teeraya; Julamanee, Jakrawadee; Saelue, Pirun; Chanswangphuwana, Chantiya; Polprasert, Chantana; Limvorapitak, Wasithep; Kanitsap, Nonglak; Wanitpongpun, Chinadol; Nakhakes, Chajchawan; Sriswasdi, Chantarapa; Prayongratana, Kannadit
- Abstract
<bold>Background: </bold>Elderly patients with acute myeloid leukemia (AML) have a poorer prognosis than younger ones. Several factors contribute to the poor outcomes for this patient group.<bold>Patients and Methods: </bold>This study investigated the epidemiology, clinical characteristics, treatment, and clinical outcomes of elderly Thai patients with AML. This 3-year, prospective, multicenter study was focused on Thai patients with AML aged over 60 years who were diagnosed between 2014 and 2016.<bold>Results: </bold>Of 680 patients with AML, 235 elderly patients with AML (34.6%) were identified, with a mean age of 70 ± 8 years. Using a 3-group cytogenetic risk classification (favorable, intermediate, and adverse risk), the proportions of patients in each category were 3.6%, 73.8%, and 22.6%, respectively. The median follow-up time for surviving patients was 846 days. The median overall survival (OS) of the patients was 128.2 days (range, 0-1205 days), with a 1-year OS of 13%. From a multivariate analysis, the significant factors associated with an improved long-term OS were patients with an Eastern Cooperative Oncology Group performance status 0 to 2 and those receiving intensive therapy.<bold>Conclusion: </bold>Our study confirms the high prevalence of AML in elderly patients with generally poor outcomes. Selected patients with a good performance status and those who received intensive induction treatment could have a long-term survival.
- Publication
Clinical Lymphoma, Myeloma & Leukemia, 2018, Vol 18, Issue 12, pe509
- ISSN
2152-2650
- Publication type
journal article
- DOI
10.1016/j.clml.2018.08.002